ARA Becomes the Latest Clinical Research Organization (CRO) to Join the iMedNet Partner Program
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that Advance Research Associates (ARA), a CRO dedicated to delivering high quality data management and biostatistical services, has selected iMedNet EDC as its preferred eClinical solution.
MedNet Solutions
, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that
Advance Research Associates
(ARA), a CRO dedicated to delivering high quality data management and biostatistical services, has selected
iMedNet EDC
as its preferred eClinical solution. As the latest member of MedNet’s growing iMedNet Partner Program, ARA will benefit from a wide range of wrap-around services designed to help ARA maximize their iMedNet EDC return on investment.
“ARA is excited to offer the iMedNet solution,” remarked Michelle Stoddard, Senior Director of Operations at ARA. “Their software as a service (SaaS) model combined with the wide ranging functionalities offered within iMedNet make this solution an ideal combination of configurability and value for a wide range of clinical study types and durations.”
“MedNet’s comprehensive, well-documented Quality Management System (QMS) gives us the security of knowing that client deliverables are the outcome of processes that meet or exceed regulatory and 21 CFR Part 11 compliance requirements,” noted Heather Zollinger, Senior Quality Systems Manager at ARA. “I am very excited about the new opportunities for both ARA and MedNet that result from this partnership.”
“MedNet is pleased to partner with ARA, a CRO known in the industry for their deep industry experience, highly experienced staff and their collaborative work approach with customers,” stated Brian Sweeney, VP of Business Development at MedNet. “We’re looking forward to a long, mutually beneficial relationship assisting ARA and their customers in meeting their clinical research objectives.”
Please contact MedNet Solutions for more information on iMedNet EDC or the iMedNet Partner Program, and ARA for additional details on their biostatistics and data management capabilities.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
